Ovidrel
PreclinicalSmall molecule
Ovidrel is one of 20 small molecule programs targeting Ovarian Reserve. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Ovarian Reserve
#DrugCompanyPhaseTrials
1Myoinositol
SSohag University
Phase 3
Co-Enzyme Q10
TTanta University
Phase 3
Thalomid
Bristol-Myers SquibbPreclinical
Remicade
Johnson & JohnsonPreclinical
Trexall
Jazz PharmaceuticalsPreclinical
Danocrine
SanofiPreclinical
Zoladex
TTerSera Therapeutics LLC
Preclinical
Growth Hormone
PfizerPreclinical
Recombinant LH
UUniversity of Colorado, Denver
Phase 2
Cetrotide
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ovidrel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMeir Medical Center